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Pancreatic b cells adapt to compensate for
increased metabolic demand during insulin resis-
tance. Although the microRNA pathway has an
essential role in b cell proliferation, the extent of its
contribution is unclear. Here, we report that miR-
184 is silenced in the pancreatic islets of insulin-
resistant mouse models and type 2 diabetic human
subjects. Reduction of miR-184 promotes the
expression of its targetArgonaute2 (Ago2), a compo-
nent of the microRNA-induced silencing complex.
Moreover, restoration of miR-184 in leptin-deficient
ob/obmice decreasedAgo2 and prevented compen-
satory b cell expansion. Loss of Ago2 during insulin
resistance blocked b cell growth and relieved the
regulation of miR-375-targeted genes, including the
growth suppressor Cadm1. Lastly, administration
of a ketogenic diet to ob/ob mice rescued insulin
sensitivity and miR-184 expression and restored
Ago2 and b cell mass. This study identifies the
targeting ofAgo2 bymiR-184 as an essential compo-
nent of the compensatory response to regulate pro-
liferation according to insulin sensitivity.
INTRODUCTION
Adaptation to environmental stress is a fundamental cellular pro-
cess that promotes the maintenance of the physiologic steady122 Cell Metabolism 19, 122–134, January 7, 2014 ª2014 Elsevier Instate (Spriggs et al., 2010). Stress responses have been shown
to induce numerous changes, such as activation of gene expres-
sion programs, which have evolved to allow for the cell to pro-
mote its own survival (Ku¨ltz, 2005; Ebert and Sharp, 2012). For
example, in response to insulin resistance, the pancreatic b
cell undertakes measures to proliferate and increase its output
of secreted insulin. A coordinated increase in both b cell mass
and secretory function constitutes the compensatory response
to maintain normoglycemia (Muoio and Newgard, 2008).
Although the underlying mechanisms directing these processes
are still not completely understood, several studies have illus-
trated a role for metabolic changes in catalyzing b cell expansion
(Steil et al., 2001). Furthermore, cellular pathways enabling the b
cells to proliferate and adapt to increases in metabolic load may
act by ultimately promoting signaling cascades essential to
increasing both secretion and islet mass (Rhodes, 2005).
Recent evidence has shown the microRNA (miRNA) pathway
as an important regulator of gene expression in response to
metabolic stress (Leung and Sharp, 2010). Central to this
mechanism are the Argonaute (Ago) proteins, which mediate
this pathway by facilitating the interaction between miRNAs
and their target mRNAs (Ho¨ck and Meister, 2008; Bartel,
2009). In addition, Ago proteins have been shown to accumulate
in stress granules upon exposure to oxidative stress; however,
their role in this compartment is not understood (Leung et al.,
2006). Although loss of Argonaute2 (Ago2) expression in the
MIN6 b cell line model resulted in enhanced secretion, its role
in the stress response of the b cell has not been described
(Tattikota et al., 2013).
We have previously shown that loss of miR-375 expression,
among the most abundant miRNA in the pancreatic islet,
inhibited the compensatory b cell proliferation in leptin-deficientc.
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Figure 1. miR-184 Is Silenced during
Insulin Resistance and Directly Targets
Argonaute2
(A) Comparison of small RNA sequencing analysis
from total RNA from islets of 12-week-old ob/ob
and wild-type (WT) littermates.
(B) Quantitative real-time PCR analysis ofmiR-184
in islets of ob/ob andWTmice from 4–16 weeks of
age (n = 3–5).
(C) Quantitative real-time PCR analysis of pri-miR-
184 in islets of ob/ob mice and WT littermates at
16 weeks of age (n = 3–5).
(D) Quantitative real-time PCR analysis ofmiR-184
in FACS-sorted b cells from 16-week-old mouse
insulin promoter-GFP mice (n = 6).
(E) Quantitative real-time PCR analysis ofmiR-184
in islets of db/db mice and WT littermates at age
12 weeks (n = 4).
(F) Quantitative real-time PCR analysis ofmiR-184
in islets of C57BL/6 mice on high-fat diet (HFD) or
chow diet.
(G) Quantitative real-time PCR analysis ofmiR-375
in islets of C57BL/6 mice on HFD or chow diet and
in islets of ob/ob mice and littermates at age
12 weeks (n = 6).
(H and I) Luciferase assays in MIN6 cells testing
direct targeting of mouse and human Ago2 genes
by miR-184 (184-mimic) or mutant (MUT-184).
(J and K) Western blot and quantitative real-time
PCR analysis of Ago2 after transfection of miR-
184-mimic and scrambled control.
(L) Quantitative real-time PCR analysis ofmiR-184
and Ago2 in islets from nondiabetic (Non) and
type-2 diabetic human subjects (T2D) after
normalization to RNU6b and TBP, respectively,
expressed as fraction of control islets. p values
represent a Mann-Whitney significance test (p =
0.009 for miR-184).
(M) Correlation of quantitative real-time PCR
analysis from (L) of Ago2 andmiR-184 in individual
T2D (n = 12) and nondiabetic (n = 15) human
subjects. Results presented as mean ± SEM. *p <
0.05; **p < 0.01; ***p < 0.001.
See also Figure S1 and Tables S1 and S2.
Cell Metabolism
Ago2 Mediates Compensatory b Cell Expansionob/ob mice and resulted in severe hyperglycemia and diabetes
(Poy et al., 2009). The absence of any dramatic effect on the
development or specification of the different cell populations in
the miR-375 knockout mouse may indicate a larger role for this
miRNA in stress responses (Mendell and Olson, 2012). Further-
more, these observations suggest that many of the targets of
miR-375 are also relevant to the adaptive response of the b
cell and likely play a role in proliferation during metabolic stress.
Although extensive sequencing efforts have identified 2,000
mature miRNA sequences in human tissues, relatively little is
understood regarding how small RNAs coordinately function in
these cellular processes (Kozomara and Griffiths-Jones, 2011).
Here, we show that miR-184 is silenced during insulin resis-
tance to promote the expression of Ago2 in the pancreatic b
cell. Deletion of Ago2 in ob/obmice reduced compensatory pro-
liferation of this cell type, thereby underlining an integral role for
the miRNA pathway in this process. Moreover, we observed that
Ago2 mediates the function of miR-375 in regulating the growth
suppressor Cadm1. Taken together, our results show that
several components of the miRNA pathway contribute in aCellconcerted effort to facilitate proliferation of the b cell to meet
metabolic demand during insulin resistance.
RESULTS
Silencing ofmiR-184 in the Pancreatic b-Cell Promotes
Its Target Argonaute2
In light of the essential role ofmiR-375 in adaptive growth of the
pancreatic b cell, we first sought to identify the additional com-
ponents of the miRNA pathway that coordinately mediate this
mechanism. We performed small RNA sequencing on total
RNA from islets of 12-week-old ob/ob mice (Table S1 available
online). Consistent with results by Zhao et al. (2009), expression
of miR-184 was the most reduced miRNA identified (Figure 1A;
Table S1). We then measured miR-184 in the islets of ob/ob
mice from age 4–16 weeks and observed the decrease in
expression starting at 8weeks of agewith the onset of resistance
(Figures 1B, S1A, and S1B). Similarly, the pri-miR-184 transcript
in the islets of ob/ob mice by quantitative real-time PCR was
also silenced, indicating that this miRNA is regulated on aMetabolism 19, 122–134, January 7, 2014 ª2014 Elsevier Inc. 123
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Ago2 Mediates Compensatory b Cell Expansiontranscriptional level (Figure 1C). As recently described, miR-184
is enriched in pancreatic b cells as shown by quantitative real-
time PCR from fluorescence-activated cell sorting (FACS)-
sorted, GFP-positive b cells (MIP-GFP) (Figure 1D) (Hara et al.,
2003; van de Bunt et al., 2013). We also observed a similar
loss of expression of mature miR-184 in the islets of 12-week-
old leptin receptor-deficient db/db mice and in mice on a high-
fat diet (HFD; 60% calories from fat), all of which showed that
this observation is not limited to one mouse model of obesity
and insulin resistance (Figures 1E and 1F). In contrast to miR-
184, miR-375 was modestly increased in HFD-fed animals as
previously observed in ob/ob mice (Figure 1G) (Poy et al.,
2009). In addition, the suppression ofmiR-184was not observed
in the eye of ob/obmice, the highest site at which expression has
been measured (Figures S1C and S1D).
In order to identify direct targets of miR-184, we induced its
expression in the MIN6 line with doxycycline after transfection
with plasmids expressing the rtTA transactivator and miR-184
under control of the operator sequence of the Escherichia coli
tetracycline-resistance operon (184-tetO). Illumina WG6v2
arrays measured changes in gene expression after 16 hr of treat-
ment with doxycycline in triplicate (Figure S1E). Several compu-
tationally predicted genes for miR-184 were downregulated in
both the array and luciferase-based experiments, including
Ago2 (Figure 1H; Figures S1F–S1H) (Friedman et al., 2009). We
cloned a portion of the mouse 30 UTR of Ago2 (912 nt) and the
complete human UTR of Ago2 (899 nt) into a luciferase reporter
construct and observed decreased activity in the presence of the
miR-184mimic. In addition, mutating six nucleotides in the bind-
ing site within the mouse or human UTR (at position 152) from
UCCGUCC to CGGGCGG abolished the inhibitory effect of
miR-184 (Figure 1H). Conversely, transfecting a mutant miR-
184 mimic had no effect on reporter activity from constructs
bearing either the mouse or human Ago2 30 UTR sequences
(Figure 1I). Western blotting after overexpression of miR-184
resulted in an approximately 60% decrease in Ago2 protein
levels, whereas quantitative real-time PCR revealed a 40%
decrease in Ago2 mRNA in MIN6 cells (Figures 1J and 1K).
To address the relevance of this microRNA:target interaction
in the islets of human subjects, we measured the expression of
miR-184 and Ago2 in the pancreatic islets from 15 nondiabetic
and 12 type 2 diabetic (T2D) donors. miR-184 was significantly
decreased in T2D islets, indicating that the expression of this
specific miRNA is linked to changes in metabolic status in both
mice and humans (Figure 1L; Table S2). Whereas levels of
Ago2 were not statistically significantly increased in T2D donor
islets compared to the nondiabetic cohort, the inverse correla-
tion between Ago2 and miR-184 expression was significant
across the entire cohort (Figure 1M).
Argonaute2 Regulates b-Cell Proliferation
We next measured Ago2 expression in the islets of insulin-resis-
tant ob/ob mice and observed increased levels at 8 weeks of
age, whereas Ago1 was not altered (Figure 2A). Similarly, Ago2
levels were increased in islets isolated from 12-week-old db/
db mice and C57BL/6 mice on a HFD for 16 weeks (Figures
2B). As shown in other tissues, Ago2 is the most abundant of
the Ago family in GFP-positive b cells as measured by quantita-
tive real-time PCR (Figures 2C and S2A) (Wang et al., 2012). To124 Cell Metabolism 19, 122–134, January 7, 2014 ª2014 Elsevier Inunderstand the contribution of Ago2 to growth and function of
the b cell, we generated transgenic mice bearing the mouse
Ago2 cDNA under the regulatory control of a tetracycline-
responsive promoter element and crossed them with mice
expressing the reverse tetracycline-controlled transactivator
(rtTA) protein under the control of the rat insulin2 (Ins-rtTA) pro-
moter as described (dox-Ago2) (Nir et al., 2007). Administration
of doxycycline via drinking water for 30 days to four different
lines (14, 30, 61, and 69) resulted in 1.5- to 25-fold increase
of Ago2 protein levels in isolated islets (Figures 2D and S2B).
Characterization of all lines showed no changes in body weight,
random glucose, or insulin levels. After a glucose challenge,
dox-Ago2 mice (line 30) exhibited transiently elevated glucose
levels compared to littermates; however, no difference was
observed in insulin sensitivity (Figures S2C and S2D). Moreover,
acute-phase plasma insulin levels were diminished after glucose
challenge, indicating reduced insulin release (Figure S2E).
Morphometric analysis in dox-Ago2 (line 30) animals showed
increased b cell mass in addition to increased insulin-positive
cell number and BrdU incorporation compared to littermates
(Figures 2E–2H).
We then established the conditional deletion in b cells by
crossing mice bearing the floxed allele of the Ago2 gene with
animals expressing Cre-recombinase under control of the rat
insulin promoter (bAgo2KO) (O’Carroll et al., 2007; Herrera,
2000). Quantitative RT-PCR and western blotting analysis
confirmed an efficient reduction in Ago2 expression in islets
from bAgo2KO mice compared to littermate controls (Figures
2I and 2J). In contrast, Ago1 was upregulated in islets isolated
from bAgo2KO mice, suggesting a degree of compensation by
this family member on the protein level (Figure 2J). Both
random-fed and fasted glucose and insulin levels were un-
changed; however, bAgo2KO mice exhibited improved glucose
tolerance without any alteration in insulin sensitivity at 10 weeks
of age compared to littermates (Figures S2F and S2G). As previ-
ously observed in the MIN6 model, loss of Ago2 expression
in vivo resulted in enhanced secretion of insulin after glucose
challenge (Figure S2H) (Tattikota et al., 2013). In contrast to
dox-Ago2 mice, we observed decreased b cell mass and
number, BrdU incorporation, and pancreatic insulin content in
bAgo2KO animals without any change in islet architecture, a
cell number, or total pancreatic mass (Figures 2K–2N, S2I, and
S2J). Moreover, no change was detected in TUNEL-positive b
cells, indicating cell death was not a primary mechanism for
the effect on b cell mass (Figure 2O). Lastly, we measured an
increase in both b cell size and the total number of granules
(Nv, measured as LDCV volume density), whereas the number
of docked granules remained unchanged (Ns, LDCV surface
density) in bAgo2KO mice compared to their littermates using
electron micrographs (Figure S2K).
Loss ofmiR-184 Expression Promotes b-Cell
Proliferation
To determine the functional role ofmiR-184 in the b cell, we char-
acterized the constitutivemiR-184-knockout mouse (184KO) for
changes in b cell proliferation, insulin release, and glucose
homeostasis. The loss of miR-184 expression resulted in
decreased fasted glucose levels and increased fasted plasma
insulin levels (Figures 3A–3C). Consistent with loss of miR-184c.
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Figure 2. Argonaute2 Is Increased during Insulin Resistance and Promotes b-Cell Proliferation
(A) Western blot analysis of Ago1 and Ago2 from islets of 8-week-old ob/ob mice and wild-type (WT) littermates.
(B) Quantitative real-time PCR analysis of Ago2 in islets after 16 weeks HFD and from 12-week-old db/db mice (n = 3–6).
(C) Quantitative real-time PCR analysis of Argonaute genes in FACS-sorted b cells from 12-week-old MIP-GFP mice (n = 3).
(D) Western blot analysis of Ago2 from islets of 10-week-old dox-Ago2 mice (line 30) and WT littermates.
(E) b cell mass analysis of 10-week-old dox-Ago2 mice (line 30) and WT (n = 3).
(F) Morphometric analysis of insulin+ and glucagon+ cells in dox-Ago2 and WT at age 10 weeks (n = 5–6).
(G and H) Ratio of BrdU (red) and insulin+ cells (green) in 10-week-old dox-Ago2 mice and WT littermates (n = 4) after immunostaining. Scale bars = 30 mm.
(I) Quantitative real-time PCR analysis of Argonaute family members in islets of 10-week-old bAgo2KO mice and littermates (n = 4).
(J) Western blot analysis of Ago2 and Ago1 from islets of 10-week-old bAgo2KO mice and WT.
(K) b cell mass analysis of 10-week-old bAgo2KO and WT mice (n = 3).
(L) Morphometric analysis of insulin+ and glucagon+ cells in bAgo2KO and littermates at 10 weeks of age (n = 5–6).
(M) Ratio of BrdU+ and insulin+ cells in bAgo2KO and littermates at 10 weeks of age (n = 5–6).
(N) Pancreatic mass to total body mass ratio of bAgo2KO and littermates at 10 weeks of age (n = 5).
(O) Ratio of TUNEL+ and insulin+ cells in bAgo2KO and littermates (n = 3). Results presented as mean ± SEM. *p < 0.05; **p < 0.01.
See also Figure S2.
Cell Metabolism
Ago2 Mediates Compensatory b Cell Expansionexpression during insulin resistance, morphometric analysis of
pancreatic sections from 184KO mice showed an increase in b
cell mass and number and BrdU incorporation rate (Figures
3D–3F). Moreover, in line with islet expression analysis in
insulin-resistant models, Ago2 expression was increased inCellmiR-184-deficient islets (Figures 3G and 3H). Knockout mice
exhibited transiently elevated insulin release and improved toler-
ance after glucose challenge, indicating additional targets, such
as Slc25a22, an established regulator of insulin release, may
mediate the effect of miR-184 on secretion (Figures S1H, S3A,Metabolism 19, 122–134, January 7, 2014 ª2014 Elsevier Inc. 125
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Figure 3. miR-184 Regulates Ago2 and Pancreatic b-Cell Proliferation In Vivo
(A) Quantitative real-time PCR analysis of miR-184 and miR-375 in islets of 10-week-old 184KO mice and wild-type (WT) littermates (n = 4).
(B) Blood glucose of 10-week-old 184KO mice and littermates (n = 4).
(C) Fasted plasma insulin levels of 10-week-old 184KO mice and littermates (n = 4).
(D) b cell mass analysis of 10-week-old 184KO and WT mice (n = 4).
(E) Morphometric analysis of insulin+ and glucagon+ cells in 184KO and WT at 10 weeks of age (n = 3).
(F) Ratio of BrdU (red) and insulin+ cells (green) in 12-week-old 184KO mice and WT (n = 3).
(G) Western blot analysis of Ago2, Slc25a22, and g-tubulin from islets of 184KO mice and WT.
(H) Quantitative real-time PCR analysis of Ago2 in islets of 10-week-old 184KO mice and littermates (n = 4–5).
(I) Blood glucose levels during an ITT on 10-week-old 184KO mice and WT (n = 4–5).
(J) Quantitative real-time PCR analysis of miR-184 in islets of 12-week-old dox-184 mice and WT mice after 15 days on doxycycline (n = 4).
(K) Plasma insulin levels of 10-week-old dox-184 mice and WT after 15 days on doxycycline (n = 4).
(L) b cell mass analysis of 10-week-old dox-184 mice and WT after 15 days on doxycycline (n = 3).
(M) Morphometric analysis of insulin+ and glucagon+ cells in 10-week-old dox-184 mice and WT (n = 4).
(N) Ratio of BrdU and insulin+ cells in dox-184 mice and WT (n = 4).
(O) Ratio of TUNEL+ and insulin+ cells in dox-184 mice and WT (n = 3).
(P) Western blot analysis of Ago2 and g-tubulin after ex vivo treatment of doxycycline on the islets of dox-184 and dox-184ob mice compared to islets from
respective control lean or ob/ob littermates. Densitometry is normalized to g-tubulin expression of ctrl-dox islets. Quantitative real-time PCR analysis ofmiR-184
in dox-184ob mice and ob/ob littermates. Results presented as mean ± SEM. *p < 0.05; **p < 0.01.
See also Figure S3.
Cell Metabolism
Ago2 Mediates Compensatory b Cell Expansionand S3B) (Casimir et al., 2009). Lastly, insulin sensitivity was
unchanged in 184KO mice, indicating that loss of this miRNA
in the b cell does not contribute to insulin resistance (Figure 3I).
Restored Expression ofmiR-184 in ob/ob Mice Inhibits
Ago2 and b-Cell Proliferation
Two gain-of-functionmodels formiR-184were then generated in
order to restore its expression in the b cell and validate the regu-126 Cell Metabolism 19, 122–134, January 7, 2014 ª2014 Elsevier Inlation of Ago2 by this miRNA during insulin resistance. Similar to
dox-Ago2 mice, Ins2-rtTA mice were crossed to newly gener-
ated mice bearing the mouse miR-184 precursor under regu-
latory control of a tetracycline-responsive promoter element
(dox-184). Administration of doxycycline for 15 days via drinking
water (1 mg/ml) resulted in 100-fold increase in expression
(Figure 3J). No change was observed in body weight; however,
dox-184 animals exhibited decreased plasma insulin levels, bc.
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Figure 4. Restoration of miR-184 during Insulin Resistance Inhibits Compensatory b-Cell Proliferation
(A) Quantitative real-time PCR analysis of miR-184 in islets of 8-week-old wild-type (WT), Tg-04, ob/ob, and 04ob mice (n = 3).
(B) Quantitative real-time PCR analysis of miR-375 in islets of 8-week-old WT, Tg-04, ob/ob, and 04ob mice (n = 4).
(C) Random blood glucose of 8-week-old WT, Tg-04, ob/ob, and 04ob mice (n = 4–12).
(D) Plasma insulin concentrations of 8-week-old WT, Tg-04, ob/ob, and 04ob mice (n = 3–6).
(E) Immunostaining analysis of pancreatic sections in 8-week-old WT, Tg-04, ob/ob, and 04ob mice for insulin (green) and glucagon (red). Scale bars = 50 mm.
(F) Pancreatic insulin content in 8-week-old WT, Tg-04, ob/ob, and 04ob mice (n = 4–6).
(G) b cell mass analysis of 10-week-old WT, Tg-04, ob/ob, and 04ob mice (n = 3).
(H) Quantification of insulin+ and glucagon+ cells per area of pancreas in WT, Tg-04, ob/ob, and 04ob mice (n = 4).
(I) Body weight analysis of WT, Tg-04, ob/ob, and 04ob mice (n = 4–12).
(J) Quantitative real-time PCR analysis of Ago2 in islets of 10-week-old WT, ob/ob, and 04ob mice (n = 4–5). Results presented as mean ± SEM. *p < 0.05;
**p < 0.01; ***p < 0.001.
See also Figure S4.
Cell Metabolism
Ago2 Mediates Compensatory b Cell Expansioncell mass and number, and BrdU incorporation (Figures 3K–3N
and S3C). The number of apoptotic cells was unchanged, indi-
cating the hyperglycemia (>250 mg/dl) and glucose intolerance
in dox-184 mice were due to a decrease in b cell mass and
rate of proliferation (Figures 3O and S3D–S3F). Isolated islets
from dox-184mice treated with doxycycline for 48 hr ex vivo ex-
hibited decreased Ago2 expression (Figure 3P). Moreover, we
crossed dox-184 mice onto the ob/ob background (dox-184ob)
and observed a 50% reduction in Ago2 expression after doxycy-
cline treatment and restoring expression ofmiR-184 (Figure 3P).
Furthermore, whereas islet levels ofmiR-375 and Ago1 were un-
changed, random blood glucose levels increased and plasma
insulin levels were significantly reduced in dox-184obmice (Fig-
ures S3G–S3J). An additional transgenic model of constitutive
overexpression was developed to further confirm the role of
miR-184 in b cell growth and function. We focused on three inde-
pendent mouse lines (Tg-96, Tg-04, and Tg-32), which showedCellby Southern analysis varying numbers of the transgene contain-
ing the miR-184 precursor sequence under control of the rat
insulin promoter (Figure S3K). All lines exhibited a mild decrease
in body weight, but the highest overexpression of miR-184
(100-fold in Tg-04 and 32) resulted in severe hyperglycemia
and reduced systemic insulin levels, whereas a 5-fold increase
(Tg-96) induced glucose intolerance and impaired insulin release
(Figures S3L–S3Q). Similar to dox-184 animals, Tg-04 and Tg-32
animals exhibited hyperglycemia and reduced circulating insulin
due to loss of b cell mass and pancreatic insulin content (Figures
4A–4G and S4A–S4G). Crossing Tg-04 animals onto the ob/ob
background (04ob) resulted in sustained expression of miR-
184 and did not compromise the most abundant miRNAs, such
as miR-375 (Figures 4A and 4B). As in dox-184ob mice, 04ob
mice exhibited severe hyperglycemia as a result of diminished
insulin levels and b cell mass and ultimately contributed toweight
loss (Figures 4C–4I). Lastly, restoring expression ofmiR-184 in bMetabolism 19, 122–134, January 7, 2014 ª2014 Elsevier Inc. 127
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Figure 5. Argonaute2 Mediates miR-375 Function in the Pancreatic b-Cell
(A) Western blot analysis of Ago2 and Cadm1 from islets of 10-week-old bAgo2KO mice and WT littermates.
(B) Quantitative real-time PCR analysis of cadm1 and miR-375 in islets of 10-week-old bAgo2KO mice and WT littermates (n = 4).
(C) Quantitative real-time PCR analysis of Cadm1, Ago1, and Ago2 after siRNA-mediated knockdown of Ago1 and Ago2 in MIN6 cells (n = 4).
(D) Western blot analysis of Ago2, Ago1, and Cadm1 after siRNA-mediated knockdown of Ago2 compared to scrambled control.
(E) Western blot analysis of Ago2 and Cadm1 in islets from 10-week-old dox-Ago2 mice and WT.
(F) Western blot analysis of Ago2, Ago1, and Cadm1 after overexpression of Ago2 compared to transfection control.
(G) Quantitative real-time PCR analysis ofCadm1 after immunopreciptation of Ago2 fromMIN6 cells untransfected (Ago2), after overexpression of Ago2 (OE), and
after inhibition of miR-375 with antisense oligonucleotides (AS375) (n = 4).
(H) b cell mass, morphometric analysis of insulin+ and glucagon+ cells, and ratio of BrdU to insulin+ cells in 18-week-old cadm1-knockout mice and littermates
(n = 4).
(I) Quantitative real-time PCR analysis ofCadm1,Gephyrin,Rasd1,Elavl4, andAgo2 in islets of ob/ob andWTmice at 16weeks of age (n = 5–6). Results presented
as mean ± SEM. *p < 0.05; **p < 0.01.
See also Figure S5.
Cell Metabolism
Ago2 Mediates Compensatory b Cell Expansioncells of 04ob mice suppressed Ago2 expression compared to
ob/ob littermates (Figure 4J).
Argonaute2 MediatesmiR-375 Function
We next measured the expression ofmiR-375-targeted genes in
islets from bAgo2KO mice and confirmed increased protein
expression in vivo (Figure S5A) (Tattikota et al., 2013).
Conversely, expression analysis of these miR-375 targets in
islets from dox-Ago2 mice showed decreased levels by quanti-
tative real-time PCR (Figure S5B). While immunoprecipitation
of Ago2 from untransfected MIN6 cells efficiently recovered
miR-375, we observed an enrichment of Gephyrin, Elavl4/HuD,
and Rasd1 in the Ago2-containing complexes compared to con-
trol pull-downs (Figures S5C and S5D). Moreover, overexpres-
sion (OE) of Ago2 recovered higher levels of these specific
mRNAs, whereas transfection of inhibitory antisense oligonucle-
otides against miR-375 (AS 375) depleted their presence in the
protein complex (Figure S5D). We also observed that expression128 Cell Metabolism 19, 122–134, January 7, 2014 ª2014 Elsevier Inof the growth suppressor Cadm1 was increased in islets of
bAgo2KO mice, further indicating that the regulation of several
targets of miR-375 was dependent on Ago2 (Figures 5A and
5B) (Poy et al., 2009). The higher levels of miR-375 target genes
were accompanied by no change in miR-375 expression, indi-
cating that the loss of Ago2 can nullify the impact of abundant
miRNAs on their respective targets (Figure 5B). We next
measured Cadm1 expression after siRNA-mediated knockdown
of Ago2 in MIN6 cells and observed a similar increase, but not
after knockdown of Ago1 (Figures 5C and 5D). In addition,
increasing Ago2 levels in both islets of dox-Ago2 mice and in
MIN6 cells (Ago2OE) decreased Cadm1 expression (Figures 5E
and 5F). As observed with the other miR-375 targets, we de-
tected enrichment of Cadm1 in Ago2-containing complexes,
indicating its regulation was also dependent upon this member
of the Ago family (Figure 5G). In line with its established role as
a growth suppressor, morphometric analysis in cadm1-deficient
mice (cadm1KO) showed increased b cell mass and number andc.
Cell Metabolism
Ago2 Mediates Compensatory b Cell ExpansionBrdU incorporation without any change in total pancreatic mass
(van der Weyden et al., 2006, 2012) (Figures 5H and S5E). Lastly,
consistent with observations in dox-Ago2 animals, quantitative
real-time PCR analysis in the islets of ob/ob mice and littermate
controls showed the miR-375 targets Cadm1, Gephyrin, Rasd1,
and Elavl4/HuD to be decreased, whereas Ago2 expression was
significantly upregulated (Figure 5I).
Loss of Argonaute2 Blocks Proliferation during Insulin
Resistance
To address whether Ago2 mediates the compensatory expan-
sion of b cells during insulin resistance, we next crossed mice
carrying the Ago2-floxed allele onto the ob/ob background to
generate mice deficient in both Ago2 and leptin (Ago2ob). In
line with bAgo2KO mice, b cell mass and the number of insu-
lin-positive cells were significantly reduced in Ago2ob animals
compared to ob/ob littermates without any alterations in the
number of glucagon-positive cells or total pancreatic mass (Fig-
ures 6A–6D). Furthermore, random glucose levels and the corre-
sponding insulin levels were decreased, thereby underlining an
important functional role for Ago2 in the growth and function of
the b cell (Figures 6E and 6F). In spite of the decrease in b cell
mass, Ago2ob mice exhibited higher circulating insulin levels
after challenge and improved glucose tolerance, confirming
again that loss of Ago2 increases secretion in vivo (Figures 6G
and 6H). Insulin sensitivity, body weight, or food intake (5.2 ±
0.4 in ob/ob and 5.0 ± 0.3 g/day in Ago2ob mice) were not signif-
icantly altered, but the decrease in both circulating glucose and
insulin suggests insulin resistance has been partially attenuated
(Figures 6I and 6J). In addition, western blotting analysis of iso-
lated islets showed that loss of Ago2 expression resulted in
increased levels of the miR-375 target Cadm1 (Figure 6K).
Similar results in islet morphometry and glucose tolerance
were observed in bAgo2KO mice placed on a HFD, indicating
that the effect on b cell mass was consistent in multiple forms
of insulin resistance and, although extrapancreatic recombina-
tion has been shown with this Cre line, including in the hypothal-
amus, energy expenditure or food intake was not affected
(Figures 6L–6O and S6A–S6D).
Administration of the Ketogenic Diet to ob/ob Mice
RestoresmiR-184 Expression
Published studies have shown that the administration of the
ketogenic diet improves insulin sensitivity and glycemic status
(Badman et al., 2009). To further support the functional relevance
of miR-184 and Ago2 in the b cell, we next tested whether miR-
184 is regulated after administering the ketogenic diet to C57BL/
6 mice (Keto mice). After 24 days on the diet, we observed 4-
fold increase of miR-184 in islets from Keto mice (Figure 7A).
As previously shown, Keto mice exhibited decreased body
weight and reduced glucose levels at steady state and during
an ITT in line with improved insulin sensitivity (Figures 7B, S7A,
and S7B). Consistent with mild 4-fold, overexpression of
miR-184, Keto mice exhibited reduced insulin levels and
impaired tolerance compared to control mice after a glucose
challenge; however, no changewas observed in b cell mass (Fig-
ures 7C, 7D, and S7C). Moreover, administration of the keto-
genic diet to ob/ob mice (Keto/ob) for 15 days was sufficient to
restore normal expression of miR-184; however, after 45 days,Cellwe observed a18-fold increase in the expression of this miRNA
in islets from Keto/ob mice compared to chow-fed, nonobese
littermate controls (Ch-WT) (Figure 7E). Keto/ob mice also ex-
hibited lower glucose levels during an ITT, reduced random
glucose and plasma insulin levels, and no change in body weight
(Figures 7F–7H, S7D, and S7E). Similar to Keto mice, Keto/ob
mice were relatively more glucose intolerant as a result of
decreased insulin release compared to Chow/ob littermates
(Figures 7I and 7J). These results may reflect a significant reduc-
tion in the demand for insulin because Keto/obmice are normo-
glycemic. Moreover, after 45 days on the ketogenic diet, we
observed a decrease in b cell mass and Ki-67+ b cells in Keto/
ob animals, and quantitative real-time PCR analysis at this time
point showed Ago2 and Slc25a22 expression to be significantly
reduced, whereas measurements produced by western blotting
showed Cadm1 to be increased (Figures 7K–7M, S7F, and S7G).
Taken together, these data further show that both miR-184 and
Ago2 expression are inversely regulated in accordance with
changes in the requirement for insulin.
DISCUSSION
Here, we show that the onset of insulin resistance induces the
silencing of miR-184 in order to promote the function of Ago2
in the pancreatic b cell. Our data suggest that miR-184 acts as
a ‘‘brake’’ on Ago2 that becomes released to increase prolifera-
tion and accommodate the elevated demand for insulin.
Moreover, we show that the increased expression of Ago2 will
facilitate the function ofmiR-375 in suppressing genes, including
Cadm1 in vivo. Our observations functionally associating miR-
184 together with Ago2 and miR-375 now identify a network
within the miRNA pathway that coordinately regulates the
compensatory proliferation of the b cell.
Interestingly, miR-184 is unique as the most downregulated
islet miRNA during insulin resistance, and additionally, adminis-
tration of the ketogenic diet in leptin-deficient ob/ob mice
rescued its expression. Furthermore, the increase of miR-184
expression in the islets of ob/ob mice after restoring insulin
sensitivity further underlines a dynamic role for the miRNA
pathway in regulating b cell growth and function according to
the demand for insulin. Published work identified the regulation
of miRNAs in the retina according to light levels, thereby linking
turnover of small RNAs with physiologic stimuli in neuronal cells;
together, our results may indicate another common property
between these cell types (Krol et al., 2010). Likewise, after
treatment with serotonin in Aplysia sea snails, miR-184 was
significantly downregulated in the nervous system, the site of
orthologous insulin expression (Rajasethupathy et al., 2009;
Floyd et al., 1999). Moreover, serotonin has been previously
shown to mediate compensatory expansion of the b cell during
pregnancy (Kim et al., 2010). In line with these studies, we
observed that miR-184 was transiently decreased at day 18.5
of gestation in C57BL/6 mice and that the expression of this
miRNA had been restored by day 5 in the postpartum phase.
Neither tryptophan hydroxlase 1 nor 2 (Tph1/2) were regulated
in the pancreatic islets of ob/ob mice, further suggesting that
multiple independent pathways promote proliferation in these
models (Rieck et al., 2009). However, the robust consistency of
the silencing ofmiR-184 in both models of pregnancy and insulinMetabolism 19, 122–134, January 7, 2014 ª2014 Elsevier Inc. 129
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Figure 6. Loss of Argonaute2 during Insulin Resistance Inhibits Compensatory Proliferation
(A) Immunostaining of pancreatic sections from Ago2ob mice and ob/ob littermates with antibodies to insulin (green) and glucagon (red). Scale bars = 200 mm.
(B) b cell mass analysis of 10-week-old wild-type (WT), ob/ob, and Ago2ob mice (n = 3).
(C) Morphometric analysis of insulin+ and glucagon+ cells in 10-week-old WT, ob/ob, and Ago2ob (n = 4–5).
(D) Pancreatic weight in 10-week-old Ago2ob mice and ob/ob littermates (n = 4–5).
(E and F) Random blood glucose and plasma insulin levels of 10-week-old Ago2ob and littermate ob/ob mice (n = 4–5).
(G) Plasma insulin levels after glucose bolus on 10-week-old Ago2ob mice and ob/ob littermates (n = 4–5).
(H) Blood glucose levels during a GTT on 10-week-old Ago2ob mice and ob/ob littermates (n = 4–5).
(I) Blood glucose levels during an ITT on 10-week-old Ago2ob mice and ob/ob littermates (n = 4–5).
(J) Body weight of Ago2ob mice and ob/ob mice from 4–10 weeks of age (n = 4–5).
(K) Western blot analysis of Ago2 and Cadm1 in islets from 10-week-old Ago2ob mice and ob/ob littermates.
(L) Blood glucose levels during a GTT on 16-week-old bAgo2KO mice and littermates after 12 weeks on a HFD (n = 6).
(M) b cell mass analysis in 16-week-old bAgo2KO mice and littermates after 12 weeks on a HFD (n = 6).
(N and O) Morphometric analysis of insulin+, glucagon+, and BrdU+ cells in 16-week-old bAgo2KOmice and littermates after 12 weeks on a HFD (n = 6). Results
presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S6.
Cell Metabolism
Ago2 Mediates Compensatory b Cell Expansionresistance suggests that additional genes in the miRNA pathway
will be identified as mediators of b cell proliferation (Jacovetti
et al., 2012).
Importantly, our results continue to build on the numerous
studies now supporting a role for miRNAs in mediating cellular
stress responses (Leung and Sharp, 2010; Mendell and Olson,130 Cell Metabolism 19, 122–134, January 7, 2014 ª2014 Elsevier In2012). The observations made in Ago2ob animals would
continue to indicate that several abundant miRNAs in the b cell
coordinately contribute to this process. In addition, our current
investigation continues to reinforce the role of miRNAs as inhib-
itors of insulin release (Poy et al., 2004; Tattikota et al., 2013;
Bolmeson et al., 2011). Although the precise role of miRNAsc.
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Figure 7. Administration of the Ketogenic Diet during Insulin Resistance Rescues miR-184 Expression
(A) Quantitative real-time PCR analysis ofmiR-184 andmiR-375 in islets of 10-week-old C57BL/6mice on chow (Chow) or ketogenic diet (Keto) for 24 days (n = 4).
(B) Blood glucose levels during an ITT on 10-week-old Chow and Keto mice for 24 days (n = 4–5).
(C and D) Plasma insulin and blood glucose levels after glucose challenge on 10-week-old Chow and Keto mice for 24 days (n = 4–5).
(E) Quantitative real-time PCR analysis of miR-184 and miR-375 in islets of 16-week-old ob/ob mice on chow or ketogenic diet and WT littermates (n = 4).
(F and G) Blood glucose and random plasma insulin levels in 16-week-old ob/ob mice on chow (Chow/ob) or ketogenic diet (Keto/ob) for 15 days (n = 4).
(H) Blood glucose levels during an ITT on 16-week-old ob/ob mice on chow or ketogenic diet for 15 days (n = 4–5).
(I and J) Plasma insulin and blood glucose levels after glucose challenge on 16-week-old ob/ob mice on chow or ketogenic diet for 15 days (n = 4-5).
(K and L) Quantification of b cell mass after immunostaining pancreatic sections for insulin (green) of 16-week-old ob/ob mice on chow or ketogenic diet for
45 days (n = 3). Scale bars = 200 mm.
(M) Quantitative real-time PCR analysis of Ago2 and Slc25a22 in islets of 16-week-old ob/ob mice on chow or ketogenic diet (n = 4–5). Results presented as
mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S7.
Cell Metabolism
Ago2 Mediates Compensatory b Cell Expansionremains unclear, the accumulating evidence may suggest that
‘‘brakes’’ on gene expression are essential in managing the
dynamic nature of both first- and second-phase insulin release
(Wang and Thurmond, 2009). Of note, the increased release of
insulin after loss of Ago2 expression in the b cells of ob/ob
mice improved many aspects of the diabetic phenotype,Cellincluding circulating glucose and insulin levels, and glucose
tolerance; however, this came at the expense of b cell mass
and may suggest that the miRNA pathway mediates a delicate
balance between both growth and secretion. Many of the genes
being targeted by small RNAs in the b cell may regulate this
balance via independent mechanisms. Several studies indicateMetabolism 19, 122–134, January 7, 2014 ª2014 Elsevier Inc. 131
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Ago2 Mediates Compensatory b Cell ExpansionF-actin and the microtubule networks are actively engaged in
managing insulin release and many of the targets of miR-375,
including Cadm1 and Gephyrin, may contribute to the remodel-
ing of the cytoskeleton (Seino et al., 2011; Charrier et al., 2010;
Masuda et al., 2010). In addition, published studies have already
shown that during pregnancy, Rasd1 acts as a growth suppres-
sor and is inhibited during islet expansion and then is increased
in the postpartum phase when islet mass is restored (Lellis-
Santos et al., 2012). Also, inhibition of the RNA-binding protein
HuD/Elavl4 was shown to promote expression of insulin (Lee
et al., 2012). Lastly, as evidenced in the differences in the pheno-
types of dox-184 and bAgo2KOmice, our observations support-
ing Slc25a22, a regulator of glutamate transport and secretion in
the b cell, as an additional target of miR-184 indicates that this
miRNA may also regulate both proliferation and exocytosis
through the targeting of different genes (Casimir et al., 2009).
Future studies will presumably continue to establish that
numerous targets of all miRNAs conspire to orchestrate the
demands placed on the cell during insulin resistance, including
growth and the continual recruitment of insulin-containing gran-
ules. It will also remain to be seen whether specificmiRNA-medi-
ated gene regulations are unique to their metabolic context,
including insulin resistance, fasting, hypoxia, and cold exposure
(Dumortier et al., 2013). Published studies have illustrated
reduced expression of miR-375 in the pancreatic islets of db/
dbmice andGoto-Kakizaki rats, suggesting that differential roles
may exist for miRNAs and their targets according to alterations in
the metabolic environment (Zhu et al., 2013; El Ouaamari et al.,
2008).
Therefore, it will be important to understand the factors that
dictate the kinetics of miRNA regulation in the b cell. It also re-
mains to be determined whether the same genes that expedite
the decay ofmiR-184 during insulin resistance are the same fac-
tors that promote its expression as sensitivity improves after
administration of the ketogenic diet. Moreover, the increase in
miR-184 that results from this diet and the resulting suppression
of insulin release indicate that miRNAs play a significant role in
the maintenance of steady-state circulating glucose and insulin
levels. Furthermore, the identification of increased miR-184
expression can explain the simultaneous occurrence of both
improved insulin sensitivity and glucose intolerance observed
in mice on ketogenic diet. Although the results appear paradox-
ical at first, this may be explained by the drastic reduction in both
circulating glucose and the demand for insulin. Another apparent
conflict appears in the mouse models exhibiting hypersecretion
and decreased b cell mass. However, in spite of the reduction in
b cell mass in Ago2obmice (35% lower compared to ob/ob litter-
mates), the decrease is significantly below the threshold that
would induce hyperglycemia (Orland et al., 1985).Ago2-deficient
models still maintain the capacity to transiently secrete higher
amounts of insulin because b cells release a relatively small per-
centage of its stored granule pool in response to glucose (Seino
et al., 2011). Conversely, although increased expression of Ago2
causes transient glucose intolerance in dox-Ago2 mice, these
mice have normal circulating glucose and insulin levels and insu-
lin sensitivity, and therefore it is unlikely that the increase in Ago2
levels in the islets of ob/obmice plays a causal role in the hyper-
glycemia or hyperinsulinemia. As shown in dox-184ob animals,
restoring miR-184 in the b cell and reducing Ago2 levels in an132 Cell Metabolism 19, 122–134, January 7, 2014 ª2014 Elsevier Ininsulin-resistant model exacerbated the diabetic phenotype. In
contrast, reducing glucose levels and the demand for insulin in
ob/ob mice by administration of ketogenic diet to ultimately
suppress Ago2 and restore b cell mass underlines an important
function this gene plays in the adaptation of the b cell according
to metabolic need.
Many aspects of b cell physiology remain largely unexplored in
terms of nutrient sensing, cellular metabolism, and intercellular
signaling pathways. Our observations on the effects of the keto-
genic diet on miRNA function in the b cell unify several poorly
understood mechanisms and reinforce the potential in studying
the role of small RNAs in physiologic stresses. Continued
emphasis on characterizing the functional role of miRNA targets
in this cell type should bring clarity in understanding how the
network of small RNAs contribute to maintaining essential meta-
bolic processes and how their failure ultimately leads to disease.
EXPERIMENTAL PROCEDURES
Generation and Maintenance of Animals
Mice were maintained on a 12 hr light/dark cycle with ad libitum access to
regular chow food, a HFD (containing 60% kcal fat, cat. no. E15741-347, ssniff
Spezialdia¨ten GmbH), or a ketogenic diet (cat. No. E15149-30, ssniff Spezial-
dia¨ten GmbH) in accordance with requirements established by Landesamt fu¨r
Gesundheit und Soziales (Lageso). All experimental procedures were
approved under protocols G 0357/10, O 0405/09, and T 0436/08. Results
were consistent in both genders; however, data from female mice are not
shown. Total Cadm1 knockouts and floxed Ago2 mice were generated as
described (van der Weyden et al., 2006; O’Carroll et al., 2007). The total
miR-184 knockout was generated by D. Aberdam and R. Shalom-Feuerstein
(Institut Clinique de la Souris) and genotyped with forward and reverse primers
50 ACTGAACATTATTTCATGGGCCGGG and 50 AACTACAACTGTTTGGCT
AGCAGGGTG (knockout allele) and the substitute reverse primer 50 CGCT
GAGACCTTGTGATAAACCGTT (wild-type allele). To generate dox-184
mice, a 292 bp genome fragment encompassing miR-184 precursor was
amplified using the primers 50 TGCTGAAGAGTGGCCTGCTAGG and 50
CTCCTCCTCACGTCCTGTGGTA, cloned into a pTRE-2 vector (Clontech),
and the resulting construct was used for microinjections. The Ago2-tetO
mice were generated from a mouse Ago2 cDNA construct (a kind gift of G.
Meister, University of Regensburg) (Nir et al., 2007).
Gene Expression Analysis in Mouse and Human Islets
Small RNA sequencing and expression analysis from cell lines and mouse
islets was performed as described; primers used with FastStart SYBR Green
PCR Master Mix (Roche) are available upon request (Tattikota et al., 2013).
Relative quantification of Ago genes was determined after normalization with
standard curves established with mouse Ago1-4 cDNA constructs
(G. Meister). RIP experiments using Ago1 and Ago2 antibodies were per-
formed as described (Keene et al., 2006). Human islets were obtained with
research consent and selected based on islet cell purity and isolated at the
University of Virginia, Oxford DRWF Human Islet Isolation Facility and Prodo
Laboratories (USA) (Mora´n et al., 2012). Information for nondiabetic and
diabetic donors is provided in Table S2.
Analytic Procedures
Insulin measurements from plasma and pancreatic extracts weremeasured by
radioimmunoassay (RIA) (Millipore), and blood glucose and luciferase assays
were measured as described previously (Poy et al., 2009). Islet morphometric
analysis after intraperitoneal injections of BrdU on four consecutive days
(50 mg/g BW, Sigma B5002) was performed on 8 mm sections of paraffin-
embedded pancreas approximately 150–200 mm apart. Sections were
dewaxed, washed, and stained for insulin (Dako A0564), glucagon (Millipore
AB932), BrdU (Abcam ab6326), Ki-67 (Dako), or TUNEL (Roche cat.
no.12156792910). Cell numbers from all islets in 3–7 sections were counted
with ImageJ software from 20X images obtained using a Zeiss LSM700c.
Cell Metabolism
Ago2 Mediates Compensatory b Cell Expansion(Schneider et al., 2012). b cell mass was measured as the ratio of insulin-
positive cell area to the total tissue area, multiplied by the weight of the
pancreas using Imaris software (Bitplane). In vivo insulin release and glucose
(GTT) or insulin (ITT) tolerance tests were performed following a 6 hr fast and
injected intraperitoneally with either glucose (2 g/kg BW) or insulin
(0.75 U/kg BW).
Cell Culture, Immunoprecipitation, and Antibodies
MIN6 cells were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen)
containing 4.5 g/l glucose supplemented with 15% v/v heat-inactivated FCS,
50 mM b-mercaptoethanol, and 50 mg/ml penicillin, and 100 mg/ml strepto-
mycin and insulin release was performed as described (Poy et al., 2004).
Antibodies were as described: Gephyrin (BD 610584), Rasd1 (Millipore
AB15794), Ago2 (for immunoprecipitation, Wako 018-22021), Ago2 (for
western blotting, Cell Signaling C34C6), Ago1 (MBL RN028PW), Slc25a22
(Sigma AV44041), HuD/Elavl4 (Santa Cruz sc-48421), g-tubulin (Sigma
T6557), Cadm1 (Sigma S4945), and b-actin (Sigma). Guinea pig anti-insulin
and rabbit anti-glucagon antibodies (Millipore) were used on paraffin-
embedded pancreata fixed in 4% paraformaldehyde for 3 hr.
Statistical Analysis
Pearson’s R coefficient and independent two-groupMann-Whitney tests were
implemented using the R statistical package (http://www.r-project.org). Com-
parisons between data sets with two groups were evaluated using an unpaired
Student’s t test. ANOVA analysis was performed for comparisons of three or
more groups. A p value of less than or equal to 0.05 was considered statisti-
cally significant. Results presented as mean ± SEM. *p < 0.05; **p < 0.01;
***p < 0.001.ACCESSION NUMBERS
The NCBI Gene Expression Omnibus (GEO) accession number for referenced
array data is GSE46623.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, Supplemental Experimental
Procedures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2013.11.015.
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